Synergy of WEE1 and mTOR inhibition in mutant KRAS-driven lung cancers

PURPOSE: KRAS-activating mutations are the most common oncogenic driver in non-small cell lung cancer (NSCLC), but efforts to directly target mutant KRAS have proved a formidable challenge. Therefore, multi-targeted therapy may offer a plausible strategy to effectively treat KRAS-driven NSCLCs. Here...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Hai, Josephine, Liu, Shengwu, Bufe, Lauren, Do, Khanh, Chen, Ting, Wang, Xiaoen, Ng, Christine, Li, Shuai, Tsao, Ming-Sound, Shapiro, Geoffrey I., Wong, Kwok-Kin
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5690829/
https://ncbi.nlm.nih.gov/pubmed/28821559
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-1098
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados